Belviso Immacolata, Sacco Anna Maria, Romano Veronica, Schonauer Fabrizio, Nurzynska Daria, Montagnani Stefania, Di Meglio Franca, Castaldo Clotilde
Department of Public Health, University of Naples Federico II.
Department of Public Health, University of Naples Federico II;
J Vis Exp. 2020 Jan 19(155). doi: 10.3791/60629.
Induced pluripotent stem cells (iPSCs) could be considered, to date, a promising source of pluripotent cells for the management of currently untreatable diseases, for the reconstitution and regeneration of injured tissues and for the development of new drugs. Despite all the advantages related to the use of iPSCs, such as the low risk of rejection, the lessened ethical issues, and the possibility to obtain them from both young and old patients without any difference in their reprogramming potential, problems to overcome are still numerous. In fact, cell reprogramming conducted with viral and integrating viruses can cause infections and the introduction of required genes can induce a genomic instability of the recipient cell, impairing their use in clinic. In particular, there are many concerns about the use of c-Myc gene, well-known from several studies for its mutation-inducing activity. Fibroblasts have emerged as the suitable cell population for cellular reprogramming as they are easy to isolate and culture and are harvested by a minimally invasive skin punch biopsy. The protocol described here provides a detailed step-by-step description of the whole procedure, from sample processing to obtain cell cultures, choice of reagents and supplies, cleaning and preparation, to cell reprogramming by the means of a commercial non-modified RNAs (NM-RNAs)-based reprogramming kit. The chosen reprogramming kit allows an effective reprogramming of human dermal fibroblast to iPSCs and small colonies can be seen as early as 24 h after the first transfection, even with modifications with the respect to the standard datasheet. The reprogramming procedure used in this protocol offers the advantage of a safe reprogramming, without the risk of infections caused by viral vector-based methods, reduces the cellular defense mechanisms, and allows the generation of xeno-free iPSCs, all critical features that are mandatory for further clinical applications.
诱导多能干细胞(iPSC)在当今可被视为一种很有前景的多能细胞来源,可用于治疗目前无法治愈的疾病、受损组织的重建与再生以及新药研发。尽管使用iPSC有诸多优势,如排斥风险低、伦理问题减少,且无论年轻或老年患者均可获取,其重编程潜力并无差异,但仍有许多问题有待克服。事实上,使用病毒及整合病毒进行细胞重编程会引发感染,导入所需基因会导致受体细胞基因组不稳定,从而影响其在临床中的应用。特别是,对于c-Myc基因的使用存在诸多担忧,多项研究表明该基因具有诱导突变的活性。成纤维细胞已成为细胞重编程的合适细胞群体,因为它们易于分离和培养,且通过微创皮肤打孔活检即可获取。本文所述方案详细逐步描述了整个过程,从样本处理以获得细胞培养物、试剂和耗材的选择、清洁与准备,到使用基于商业非修饰RNA(NM-RNA)的重编程试剂盒进行细胞重编程。所选用的重编程试剂盒能够有效地将人真皮成纤维细胞重编程为iPSC,甚至在首次转染后24小时即可观察到小菌落,即便与标准数据表有所不同。本方案中使用的重编程方法具有安全重编程的优势,不会有基于病毒载体方法所导致的感染风险,降低了细胞防御机制,并能够生成无动物成分的iPSC,所有这些关键特性对于进一步的临床应用都是必不可少的。